MedTrace Logo

A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

NCT00144053 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2006-01-06

No results posted yet for this study

Summary

To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.

Conditions

Interventions

DRUG

Cisplatin+Vindesine+MMC/ concurrent radiation

DRUG

Irinotecan+Carboplatin/concurrent radiation

DRUG

Paclitaxel+Carboplatin/concurrent radiation

Sponsors & Collaborators

  • West Japan Thoracic Oncology Group

    lead OTHER

Principal Investigators

  • Hisao Uejima, MD · West Japan Thoracic Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144053 on ClinicalTrials.gov